3D pharmacophore based virtual screening of T-type calcium channel blockers

被引:37
作者
Doddareddy, Munikumar Reddy
Choo, Hyunah
Cho, Yong Seo
Rhim, Hyewhon
Koh, Hun Yeong
Lee, Jung-Ha
Jeong, Seong-Woo
Pae, Ae Nim
机构
[1] Korea Inst Sci & Technol, Div Life Sci, Seoul 130650, South Korea
[2] Sogang Univ, Dept Life Sci, Seoul 121742, South Korea
[3] Yonsei Univ, Wonju Coll Med, Dept Physiol, Wonju 220701, Kangwon Do, South Korea
关键词
virtual screening; pharmacophore; T-type calcium channel blockers;
D O I
10.1016/j.bmc.2006.10.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening of the commercial databases was done by using a three dimensional pharmacophore previously developed for T-type calcium channel blockers using CATALYST (TM) program. Biological evaluation of 25 selected virtual hits resulted in the discovery of a highly potent compound VH04 with IC50 value of 0.10 mu M, eight times as potent as the known selective T-type calcium channel blocker, mibefradil. Search for similar compounds yielded several hits with micro-molar IC50 values and high T-type calcium channel selectivity. Based on the structure of the virtual hits, small molecule libraries with novel scaffolds were designed, synthesis and biological evaluation of which are currently in progress. This result shows a successful example of ligand based drug discovery of potent T-type calcium channel blockers. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1091 / 1105
页数:15
相关论文
共 24 条
[1]   Calcium-antagonist drugs [J].
Abernethy, DR ;
Schwartz, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (19) :1447-1457
[2]  
*ACC INC, 2001, CAT SOFTW
[3]   Choosing the most appropriate treatment for stable angina - Safety considerations [J].
Asirvatham, S ;
Sebastian, C ;
Thadani, U .
DRUG SAFETY, 1998, 19 (01) :23-44
[4]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[5]   Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil [J].
Cremers, B ;
Flesch, M ;
Sudkamp, M ;
Bohm, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (05) :692-696
[6]   First pharmacophoric hypothesis for T-type calcium channel blockers [J].
Doddareddy, MR ;
Jung, HK ;
Lee, JY ;
Lee, YS ;
Cho, YS ;
Koh, HY ;
Pae, AN .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (07) :1605-1611
[7]   T-type Ca2+ channels and pharmacological blockade:: Potential pathophysiological relevance [J].
Ertel, SI ;
Ertel, EA ;
Clozel, JP .
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (06) :723-739
[8]   Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the alpha(1) subunit [J].
Hockerman, GH ;
Johnson, BD ;
Abbott, MR ;
Scheuer, T ;
Catterall, WA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) :18759-18765
[9]   Painful neuropathy decreases membrane calcium current in mammalian primary afferent neurons [J].
Hogan, QH ;
McCallum, JB ;
Sarantopoulos, C ;
Aason, M ;
Mynlieff, M ;
Kwok, WM ;
Bosnjak, ZJ .
PAIN, 2000, 86 (1-2) :43-53
[10]  
HUGUENARD JR, 1994, J NEUROSCI, V14, P5485